Download this Press Release as a PDF IngenOx Therapeutics –26th February 2025, the Oxford-based biopharmaceutical company, announced today positive interim results from its Phase 2 clinical trial investigating zabadinostat in combination with a PD-1 inhibitor for advanced hepatocellular carcinoma (HCC).…
Download this Press Release as a PDF IngenOx Therapeutics, the Oxford biopharma company, focused on developing novel cancer therapeutics, announced today that its Chief Medical Officer, Prof. David Kerr has been awarded the China Friendship Medal. Ingenox is pleased to…
IngenOx Therapeutics, the Oxford biopharma company focused on developing novel cancer therapeutics, provided today a company update on its board reshuffle. In the revised board, Patrick Soon-Shiong, M.D. joins as Chairman. Leonard S. Sender, M.D. and Sandeep “Bobby” Reddy, M.D.…
Oxford, UK – 07 Dec 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based biopharmaceutical company, announced that its Chief Medical Officer, Prof. David Kerr had published a review on the use of diagnostic biomarkers to personalise…
Oxford, UK – 6 October 2023 Download this Press Release as a PDF IngenOx Therapeutics, the Oxford-based biopharmaceutical company announced today that it had received separate grants of applications from the Chinese (CNIPA); and European Patent Office for compounds and…